182 related articles for article (PubMed ID: 32767682)
1. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma.
McPherson V; Reardon B; Bhayankara A; Scott SN; Boyd ME; Garcia-Grossman IR; Regazzi AM; McCoy AS; Kim PH; Al-Ahmadie H; Ostrovnaya I; Roth AJ; Farooki A; Berger MF; Rosenberg JE; Solit DB; Van Allen E; Milowsky MI; Bajorin DF; Iyer G
Cancer; 2020 Oct; 126(20):4532-4544. PubMed ID: 32767682
[TBL] [Abstract][Full Text] [Related]
2. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.
Wen PY; Touat M; Alexander BM; Mellinghoff IK; Ramkissoon S; McCluskey CS; Pelton K; Haidar S; Basu SS; Gaffey SC; Brown LE; Martinez-Ledesma JE; Wu S; Kim J; Wei W; Park MA; Huse JT; Kuhn JG; Rinne ML; Colman H; Agar NYR; Omuro AM; DeAngelis LM; Gilbert MR; de Groot JF; Cloughesy TF; Chi AS; Roberts TM; Zhao JJ; Lee EQ; Nayak L; Heath JR; Horky LL; Batchelor TT; Beroukhim R; Chang SM; Ligon AH; Dunn IF; Koul D; Young GS; Prados MD; Reardon DA; Yung WKA; Ligon KL
J Clin Oncol; 2019 Mar; 37(9):741-750. PubMed ID: 30715997
[TBL] [Abstract][Full Text] [Related]
3. Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations.
Bardia A; Gounder M; Rodon J; Janku F; Lolkema MP; Stephenson JJ; Bedard PL; Schuler M; Sessa C; LoRusso P; Thomas M; Maacke H; Evans H; Sun Y; Tan DSW
Oncologist; 2020 Jan; 25(1):e160-e169. PubMed ID: 31395751
[TBL] [Abstract][Full Text] [Related]
4. Effect of Buparlisib, a Pan-Class I PI3K Inhibitor, in Refractory Follicular and Poorly Differentiated Thyroid Cancer.
Borson-Chazot F; Dantony E; Illouz F; Lopez J; Niccoli P; Wassermann J; Do Cao C; Leboulleux S; Klein M; Tabarin A; Eberle MC; Benisvy D; de la Fouchardière C; Bournaud C; Lasolle H; Delahaye A; Rabilloud M; Lapras V; Decaussin-Petrucci M; Schlumberger M
Thyroid; 2018 Sep; 28(9):1174-1179. PubMed ID: 30105951
[TBL] [Abstract][Full Text] [Related]
5. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
6. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
Garrido-Castro AC; Saura C; Barroso-Sousa R; Guo H; Ciruelos E; Bermejo B; Gavilá J; Serra V; Prat A; Paré L; Céliz P; Villagrasa P; Li Y; Savoie J; Xu Z; Arteaga CL; Krop IE; Solit DB; Mills GB; Cantley LC; Winer EP; Lin NU; Rodon J
Breast Cancer Res; 2020 Nov; 22(1):120. PubMed ID: 33138866
[TBL] [Abstract][Full Text] [Related]
7. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A; Johnston S; Lee KS; Ciruelos E; Lønning PE; Janni W; O'Regan R; Mouret-Reynier MA; Kalev D; Egle D; Csőszi T; Bordonaro R; Decker T; Tjan-Heijnen VCG; Blau S; Schirone A; Weber D; El-Hashimy M; Dharan B; Sellami D; Bachelot T
Lancet Oncol; 2018 Jan; 19(1):87-100. PubMed ID: 29223745
[TBL] [Abstract][Full Text] [Related]
8. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.
Geuna E; Milani A; Martinello R; Aversa C; Valabrega G; Scaltriti M; Montemurro F
Expert Opin Investig Drugs; 2015 Mar; 24(3):421-31. PubMed ID: 25645727
[TBL] [Abstract][Full Text] [Related]
9. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D; Faivre S; Mesía R; Remenár É; Li SH; Karpenko A; Dechaphunkul A; Ochsenreither S; Kiss LA; Lin JC; Nagarkar R; Tamás L; Kim SB; Erfán J; Alyasova A; Kasper S; Barone C; Turri S; Chakravartty A; Chol M; Aimone P; Hirawat S; Licitra L
Lancet Oncol; 2017 Mar; 18(3):323-335. PubMed ID: 28131786
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor-targeted therapies.
McKay RR; De Velasco G; Werner L; Bellmunt J; Harshman L; Sweeney C; Rosenberg JE; Hirsch M; Signoretti S; Van Allen EM; Walsh M; Vaishampayan U; McDermott DF; Choueiri TK
Cancer; 2016 Aug; 122(15):2389-98. PubMed ID: 27198170
[TBL] [Abstract][Full Text] [Related]
11. Pan-phosphatidylinositol 3-kinase inhibition with buparlisib in patients with relapsed or refractory non-Hodgkin lymphoma.
Younes A; Salles G; Martinelli G; Bociek RG; Barrigon DC; Barca EG; Turgut M; Gerecitano J; Kong O; Pisal CB; Tavorath R; Kim WS
Haematologica; 2017 Dec; 102(12):2104-2112. PubMed ID: 28971900
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.
Armstrong AJ; Halabi S; Healy P; Alumkal JJ; Winters C; Kephart J; Bitting RL; Hobbs C; Soleau CF; Beer TM; Slottke R; Mundy K; Yu EY; George DJ
Eur J Cancer; 2017 Aug; 81():228-236. PubMed ID: 28502694
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study.
Vansteenkiste JF; Canon JL; De Braud F; Grossi F; De Pas T; Gray JE; Su WC; Felip E; Yoshioka H; Gridelli C; Dy GK; Thongprasert S; Reck M; Aimone P; Vidam GA; Roussou P; Wang YA; Di Tomaso E; Soria JC
J Thorac Oncol; 2015 Sep; 10(9):1319-1327. PubMed ID: 26098748
[TBL] [Abstract][Full Text] [Related]
14. Benefits versus risk profile of buparlisib for the treatment of breast cancer.
Patsouris A; Augereau P; Frenel JS; Robert M; Gourmelon C; Bourbouloux E; Berton-Rigaud D; Chevalier LM; Campone M
Expert Opin Drug Saf; 2019 Jul; 18(7):553-562. PubMed ID: 31159599
[No Abstract] [Full Text] [Related]
15. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma.
Seront E; Rottey S; Filleul B; Glorieux P; Goeminne JC; Verschaeve V; Vandenbulcke JM; Sautois B; Boegner P; Gillain A; van Maanen A; Machiels JP
BJU Int; 2016 Sep; 118(3):408-15. PubMed ID: 26779597
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of the Pan-PI3K Inhibitor Buparlisib in Adult Chinese Patients with Advanced Solid Tumors.
Wu YL; Zhang LI; Trandafir L; Dong T; Duval V; Hazell K; Xu B
Anticancer Res; 2016 Nov; 36(11):6185-6194. PubMed ID: 27793950
[TBL] [Abstract][Full Text] [Related]
17. PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Guerin M; Rezai K; Isambert N; Campone M; Autret A; Pakradouni J; Provansal M; Camerlo J; Sabatier R; Bertucci F; Charafe-Jauffret E; Hervieu A; Extra JM; Viens P; Lokiec F; Boher JM; Gonçalves A
Eur J Cancer; 2017 Nov; 86():28-36. PubMed ID: 28950146
[TBL] [Abstract][Full Text] [Related]
18. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Al-Ali R; Krake S; Radefeldt M; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457111
[TBL] [Abstract][Full Text] [Related]
19. Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Campone M; Im SA; Iwata H; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Cortés J; De Laurentiis M; Arteaga CL; Jiang Z; Jonat W; Le Mouhaër S; Sankaran B; Bourdeau L; El-Hashimy M; Sellami D; Baselga J
Eur J Cancer; 2018 Nov; 103():147-154. PubMed ID: 30241001
[TBL] [Abstract][Full Text] [Related]
20. A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.
McRee AJ; Marcom PK; Moore DT; Zamboni WC; Kornblum ZA; Hu Z; Phipps R; Anders CK; Reeder-Hayes K; Carey LA; Weck KE; Perou CM; Dees EC
Clin Breast Cancer; 2018 Aug; 18(4):289-297. PubMed ID: 29153866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
